share_log

Time To Worry? Analysts Are Downgrading Their WuXi AppTec Co., Ltd. (SHSE:603259) Outlook

Time To Worry? Analysts Are Downgrading Their WuXi AppTec Co., Ltd. (SHSE:603259) Outlook

是时候担心了吗?分析师正在下调无锡药明康德有限公司(SHSE: 603259)展望的评级
Simply Wall St ·  03/20 19:11

The analysts covering WuXi AppTec Co., Ltd. (SHSE:603259) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Both revenue and earnings per share (EPS) estimates were cut sharply as analysts factored in the latest outlook for the business, concluding that they were too optimistic previously.

报道无锡药明康德有限公司(SHSE: 603259)的分析师今天对今年的法定预测进行了实质性修订,从而向股东传递了一定负面情绪。由于分析师将最新的业务前景考虑在内,得出结论,他们此前过于乐观,因此收入和每股收益(EPS)的预期均大幅下调。

Following the latest downgrade, WuXi AppTec's 24 analysts currently expect revenues in 2024 to be CN¥40b, approximately in line with the last 12 months. Statutory earnings per share are presumed to accumulate 3.7% to CN¥3.40. Prior to this update, the analysts had been forecasting revenues of CN¥48b and earnings per share (EPS) of CN¥3.96 in 2024. It looks like analyst sentiment has declined substantially, with a measurable cut to revenue estimates and a real cut to earnings per share numbers as well.

继最近的降级之后,药明康德的24位分析师目前预计2024年的收入将达到400亿元人民币,与过去12个月大致持平。假定每股法定收益将累计3.7%至3.40元人民币。在本次更新之前,分析师一直预测2024年的收入为480亿元人民币,每股收益(EPS)为3.96元人民币。看来分析师的情绪已大幅下降,收入预期大幅下调,每股收益数字也实际下调。

earnings-and-revenue-growth
SHSE:603259 Earnings and Revenue Growth March 20th 2024
SHSE: 603259 2024 年 3 月 20 日收益和收入增长

It'll come as no surprise then, to learn that the analysts have cut their price target 27% to CN¥82.59.

因此,得知分析师已将目标股价下调27%至82.59元人民币也就不足为奇了。

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 1.4% by the end of 2024. This indicates a significant reduction from annual growth of 31% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 17% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - WuXi AppTec is expected to lag the wider industry.

从现在的大局来看,我们可以理解这些预测的方法之一是看看它们如何与过去的业绩和行业增长预期相比较。这些估计表明,预计销售将放缓,预计到2024年底,年化收入将下降1.4%。这表明与过去五年的31%的年增长率相比大幅下降。相比之下,我们的数据表明,在可预见的将来,预计同一行业的其他公司(有分析师报道)的收入每年将增长17%。因此,尽管预计其收入将萎缩,但这种云并没有带来一线希望——预计药明康德将落后于整个行业。

The Bottom Line

底线

The most important thing to take away is that analysts cut their earnings per share estimates, expecting a clear decline in business conditions. Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that WuXi AppTec's revenues are expected to grow slower than the wider market. After such a stark change in sentiment from analysts, we'd understand if readers now felt a bit wary of WuXi AppTec.

要了解的最重要的一点是,分析师下调了每股收益预期,预计业务状况将明显下降。不幸的是,分析师也下调了收入预期,行业数据表明,药明康德的收入增长预计将慢于整个市场。在分析师的观点发生了如此明显的变化之后,我们可以理解读者现在是否对药明康德有些警惕。

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. We have estimates - from multiple WuXi AppTec analysts - going out to 2026, and you can see them free on our platform here.

即便如此,业务的长期发展轨迹对于股东的价值创造更为重要。根据多位无锡AppTec分析师的估计,到2026年,你可以在我们的平台上免费查看。

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

寻找可能达到转折点的有趣公司的另一种方法是使用内部人士收购的成长型公司的免费清单,跟踪管理层是买入还是卖出。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发